Status:

TERMINATED

Analysis of Antihypertensive Treatment Efficacy

Lead Sponsor:

AstraZeneca

Conditions:

Arterial Hypertension

Eligibility:

All Genders

18+ years

Brief Summary

Analysis of antihypertensive treatment efficacy.

Eligibility Criteria

Inclusion

  • arterial hypertension
  • intake of Atacand before study enrollment

Exclusion

  • hypersensitivity to candesartan or any other ingredient of Atacand
  • liver function impairment and/or cholestasis
  • severe renal insufficiency (serum creatinine \> 265 µmol/L)
  • Pregnant and lactating women

Key Trial Info

Start Date :

May 1 2008

Trial Type :

OBSERVATIONAL

Allocation :

ESTIMATED

End Date :

February 1 2009

Estimated Enrollment :

2000 Patients enrolled

Trial Details

Trial ID

NCT00767247

Start Date

May 1 2008

End Date

February 1 2009

Last Update

December 3 2010

Active Locations (13)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 4 (13 locations)

1

Research Site

Arhangelsk, Russia

2

Research Site

Bryansk, Russia

3

Research Site

Domodedovo, Russia

4

Research Site

Dzerzhinsk, Russia